Phase I Study of Cancer Vaccine Therapy Using Epitope Peptide Restricted to HLA-A02 (URLC10) in Patients With Non-small Cell Lung Cancer Refractory to Standard Therapy.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs URLC10 peptide vaccine (Primary) ; Montanide ISA-51
- Indications Non-small cell lung cancer
- Focus Adverse reactions
Most Recent Events
- 19 Mar 2019 Biomarkers information updated
- 17 Sep 2013 Planned end date changed from 1 Oct 2013 to 1 Oct 2015 as reported by ClinicalTrials.gov.
- 06 May 2012 New source identified and integrated (University Hospital Medical Information Network - Japan; UMIN000003190).;